Madhav Vissa. ATP III  Adult Treatment Panel  Guidelines for tx of High Cholesterol  Based on epidemiological evidence about risk factors for CHD.

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Robert M. Guthrie, MD Professor of Emergency Medicine
YOUR CHOLESTEROL WHY DO YOU CARE? WHAT YOU CAN DO !
Lipid Management Standard and Advanced Preview of ATP-IV
NCEP ATP IV GuidelineS: 2013 Update
NCEP ATP III Cholesterol Guidelines and Updates
Metabolic & Endocrine Disease Summit Dyslipidemia and Current Guidleines for Lipid Management Thursday July 28, 2011 Orlando, FL Joyce L. Ross, MSN, CRNP,
Lipid Management in 2015: Risk & Controversies
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
CVD risk estimation and prevention: An overview of SIGN 97.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Lipids 101 Cardiology Board Review Med-Peds Style!
Final Exam Tuesday, 6/5, 2 PM Closed book – Essay and MC/TF Determining Energy Needs – p – Indirect calorimetry – Be able to do the calculations.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Understanding blood lipids and glucose How a Healthy Lifestyle can improve your numbers Susan Fullmer, PhD RD Associate Teaching Professor Nutrition, Dietetics,
Cardiovascular Disease in Women Module III: Risk Assessment Tool.
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Adult Treatment Panel III (ATP III) Guidelines
Cholesterol. CHOLESTEROL What is it? How does it cause heart disease? A fat like substance in your blood When there is too much cholesterol in your blood,
 Screening › Who needs screened? › How often?  Diagnosis  Treatment  Questions › What do I do about triglycerides? › What if a patient isn’t at goal?
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Update Lipid Management in Chronic Kidney Disease 成大醫院心臟內科 李政翰醫師 助理教授.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
LDL-C target levels (mg/dL)  2 RF:
Department of Family & Community Medicine
Cardiovascular Disease
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
CHRISTIAN SONNIER MD 7/15/14 Hyperlipidemia:. Hyperlipidemia Definition: an elevation of total cholesterol and or LDL with or without decrease in HDL.
Dyslipidemia: What Every Resident Should Know
Hypertension, Cardiovascular Disease, Diabetes. 34% of Americans 36% of Americans.
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Risk Factors for Cardiovascular Disease
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
? OTC LOVASTATIN Jesse M. Polansky M.D., M.P.H. Representing self.
International Guidelines for Prevention of Atherosclerotic Cardiovascular Disease Prof. Mohamed Sobhy, MD, FACC Professor of Cardiology, Alex. University.
Cholesterol. What is cholesterol? Waxy, fat-like substance found in all cells. Dietary cholesterol – found only in animal-based foods Blood cholesterol.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.
Hyperlipidaemiák Szollár Lajos Klinikai kórélettan Szeptember 28.
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease Department of Nephrology R3. Yeehyung Kim.
National Cholesterol Education Program
Classification of total cholesterol levels
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
NCEP/Framingham risk scores: Estimate of 10-yr CHD risk in men without CHD VBWG Age (y) 20–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
New LDL-C Lipid Targets
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Description of studies for pooled analyses
I. Introduction American Journal of Kidney Diseases
Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Goals & Guidelines A summary of international guidelines for CHD
Cardiovascular Disease in Women Module III: Risk Assessment Tool
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease  Dean G. Karalis, MD  Mayo Clinic Proceedings 
III. Treating dyslipidemias
Special Considerations for Different Population Groups
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Presentation transcript:

Madhav Vissa

ATP III  Adult Treatment Panel  Guidelines for tx of High Cholesterol  Based on epidemiological evidence about risk factors for CHD

↑ Cholesterol  ↑ CHD Risk

5 steps to determine risk  Step 1 – Lipid Profile  Step 2 – CHD Equivalents CHD is a risk factor for coronary events, other things are too. ○ DM ○ Symptomatic CAD ○ Peripheral artery dz ○ AAA ○ Chronic Kidney Dz

More Steps  Step 3 – Other major Risk factors (not LDL) Smoking, HTN, Low HDL (<40), Fam Hx, Older age  Stage 4 – ≥ 2 risk factors +/- CHD Equivalent

Based on Framingham risk tables – may overestimate risk in European and Asian Populations Do not need to do this in pt with 1 or fewer risk factors (10 year risk of CHD is <10%)

Step 5  “determine the risk category that establishes the LDL goal” More risk factors = lower LDL more Initiate drug therapy if LDL cannot be lowered to desired level with lifestyle changes

References  UpToDate - ATP III guidelines for treatment of high blood cholesterol